Clinical Trial Update: Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS [Phase 3]

View source ↗

Summary

A Phase 3 trial of a recombinant anti-human IL-17A/F monoclonal antibody for moderate-to-severe active ankylosing spondylitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Recombinant anti-human IL-17A/F monoclonal antibody (anti-IL-17A/F monoclonal antibody)

Snippet

Sponsor: Zhejiang Kanova Biopharmaceutical Co., LTD | Conditions: Phase III | Phase 3 | Status: COMPLETED